Preclinical Review Links Kratom to Epigenetic Changes and Cardiac Risks

The Clinical Dilemma of Botanical Opioid Alternatives

As the opioid crisis continues to limit access to traditional analgesics, an increasing number of patients are turning to kratom (Mitragyna speciosa) for the self-management of chronic pain and opioid withdrawal [1, 2]. While marketed as a natural supplement, this botanical contains complex alkaloids such as mitragynine, which functions as a partial mu-opioid agonist (a compound that binds to and activates opioid receptors but with lower maximal efficacy than full agonists like morphine), leading to documented physical dependence and neonatal abstinence syndrome [3, 4]. Clinical reports have linked its use to severe adverse events, including cholestatic liver injury (a condition where bile flow from the liver is slowed or blocked) and a 1,200% increase in poison control center calls between 2015 and 2025 [5, 6]. Despite its widespread availability, the lack of standardized dosing and rigorous pharmacokinetic data (the study of how the body absorbs, distributes, and eliminates a substance) leaves physicians with little guidance on managing patients who use these products [7, 8]. A new systematic review of 20 studies clarifies the underlying molecular landscape, revealing that chronic exposure may increase the expression of histone deacetylase 2 (an enzyme that modifies gene regulation) and identifies Rab35 as a potential protein biomarker for withdrawal [9].

Multimodal Receptor Activity and Neurotransmitter Modulation

Mitragynine serves as the primary bioactive constituent in kratom, driving a complex pharmacological profile that bridges the gap between analgesia and stimulation. This systematic review of 20 studies highlights that kratom alkaloids are not limited to a single pathway; instead, they engage μ-opioid receptors (the primary targets for traditional narcotic analgesics), adrenergic receptors (which mediate the sympathetic nervous system's response and contribute to stimulant effects), and serotonergic receptors (which influence mood and pain perception). This multimodal binding profile explains why patients often report a paradoxical combination of sedation and increased alertness. For the clinician, this means that a patient's presentation may vary wildly based on dosage, as the substance mimics both the calming effects of opioids and the excitatory effects of stimulants. Beyond direct receptor binding, the researchers found that these alkaloids modulate dopaminergic systems (the brain's reward and motor control pathways) and glutamatergic systems (the primary excitatory signaling network in the central nervous system). This broad neurochemical influence allows kratom to exert significant anti-inflammatory and analgesic effects, providing a mechanistic basis for its use in pain management. However, by influencing glutamate and dopamine, the botanical may also drive the neuroplasticity associated with substance use disorders, suggesting that the same pathways providing relief may simultaneously facilitate the transition to dependence.

Epigenetic Drivers of Dependence and Withdrawal

Chronic exposure to mitragynine followed by withdrawal is associated with reduced histone acetylation, a chemical modification that typically relaxes the structure of DNA to allow for gene transcription. The researchers found that this reduction in acetylation is closely linked to increased expression of histone deacetylase 2 (HDAC2), an enzyme that removes acetyl groups from histones and effectively silences specific genes. For the practicing physician, these findings suggest that kratom dependence is not merely a transient state of receptor occupancy but involves an epigenetic remodeling of the brain's reward and stress circuits. This molecular shift may explain why patients experience persistent cravings and significant difficulty during cessation, as the upregulation of HDAC2 creates a stable cellular environment that reinforces the cycle of dependence. Furthermore, the study identified Rab35 (a protein involved in intracellular membrane trafficking and the transport of proteins within the cell) as a potential biomarker associated with kratom withdrawal. The emergence of Rab35 suggests that the cellular response to the cessation of mitragynine involves distinct alterations in how neurons process and transport essential signaling molecules. While current clinical management of kratom cessation often relies on symptomatic relief, these molecular insights into HDAC2 and Rab35 provide a foundation for future diagnostic tools that could objectively identify withdrawal states and guide targeted therapeutic interventions.

Systemic Risks and Barriers to Clinical Use

Mitragynine significantly inhibited cardiac ion channels, which are the essential protein pathways that regulate the flow of ions across cell membranes to maintain a steady heartbeat. This finding raises substantial safety concerns regarding cardiotoxicity, as disruptions in these channels can lead to arrhythmias or other conduction abnormalities in patients using kratom. Furthermore, the data indicate that mitragynine altered the expression of cytochrome P450 (CYP450) enzymes, the primary family of enzymes in the liver responsible for metabolizing the majority of pharmaceutical drugs. For the clinician, this is a critical safety signal: it suggests a high potential for drug-drug interactions, where kratom could either increase the toxicity or decrease the efficacy of a patient's concurrent medications, such as anticoagulants or antidepressants, by interfering with their metabolic clearance. Despite these mechanistic insights, the authors noted that limitations in pharmacokinetic data, standardized dosing, and long-term safety currently preclude clinical application. Without a clear understanding of how mitragynine behaves over time in the human body, the risk-to-benefit ratio remains unfavorable. To address these gaps, the researchers identified several future research priorities, including controlled human studies and omics-driven biomarker discovery (the use of large-scale data from genes, proteins, or metabolites to find indicators of health or disease). These steps are necessary to establish whether kratom can ever be safely utilized under medical supervision.

Methodological Framework of the Systematic Review

The researchers utilized a rigorous methodological framework to synthesize preclinical evidence regarding the molecular, pharmacological, and epigenetic effects of kratom. To ensure transparency, the authors followed the PRISMA 2020 criteria, a standardized 27-item checklist known as the Preferred Reporting Items for Systematic Reviews and Meta-Analyses designed to improve the quality and replicability of evidence synthesis. The search strategy targeted two primary academic databases, Scopus and Web of Science, covering a 24-year period of literature published between 2000 and 2024. From the initial search results, the researchers identified 20 eligible studies that met the inclusion criteria for detailed analysis. The review focused specifically on the mechanisms of action within in vitro models (experiments conducted in controlled environments outside of a living organism, such as cell cultures) and in vivo models (studies performed within living organisms, such as mice or rats). By analyzing these diverse experimental frameworks, the authors mapped receptor activity, intracellular signaling, and gene regulation associated with kratom alkaloids. This systematic approach provided a detailed look at how these compounds interact with biological systems at the cellular level, offering a foundation for understanding the physiological risks and therapeutic limitations observed in preclinical settings.

References

1. Edinoff AN, Kaufman SE, Mahoney TC, et al. Kratom: A Narrative Review of the Possible Clinical Uses and Dangers of This Opioid-Like Plant. Cureus. 2024. doi:10.7759/cureus.73058

2. Prozialeck WC, Lamar PC, Krupp M, Moon MJ, Phelps LE, Grundmann O. Kratom Use Within the Context of the Evolving Opioid Crisis and the COVID-19 Pandemic in the United States. Frontiers in Pharmacology. 2021. doi:10.3389/fphar.2021.729220

3. Harun N, Kamaruzaman NA, Sofian ZM, Hassan Z. Mini review: Potential therapeutic values of mitragynine as an opioid substitution therapy.. Neuroscience letters. 2022. doi:10.1016/j.neulet.2022.136500

4. Abdullah MFILB. Kratom Dependence and Treatment Options: A Comprehensive Review of the Literature. Current Drug Targets. 2020. doi:10.2174/1389450121666200719011653

5. Calicdan XA, Kopczynski A, Medina E, et al. Liver Injury Associated With Kratom ( Mitragyna speciosa ): A Systematic Review.. Journal of addiction medicine. 2026. doi:10.1097/ADM.0000000000001663

6. Towers EB, Thomas YT, Holstege CP, Farah R. Increases in Kratom-Related Reports to Poison Centers — National Poison Data System, United States, 2015–2025. MMWR Morbidity and Mortality Weekly Report. 2026. doi:10.15585/mmwr.mm7511a1

7. Stanciu CN, Ahmed S, Gnanasegaram SA, et al. Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature. The American Journal of Drug and Alcohol Abuse. 2022. doi:10.1080/00952990.2022.2111685

8. Tanna RS, Nguyen J, Hadi DL, et al. Clinical Pharmacokinetic Assessment of Kratom (Mitragyna speciosa), a Botanical Product with Opioid-like Effects, in Healthy Adult Participants. Pharmaceutics. 2022. doi:10.3390/pharmaceutics14030620

9. Misnan E, Hasbullah NZA, RASHID RA, Shah AM, Sim MS. Decoding kratom: molecular mechanisms and epigenetic factors in use and dependence. Translational Psychiatry. 2026. doi:10.1038/s41398-026-04022-5